Cardiavent Inc.
3991 Ramsgate Ct.
Ann Arbor, MI 48013

CARD-024 Development

  • CARD-024 is non-hypercalcemic, selective vitamin D receptor agonist under development for the treatment of cardiovascular disease, secondary hyperparathyroidism in chronic kidney disease and intestinal bowel disease fibrosis.
  • A Phase 1 randomized, placebo-controlled clinical study evaluated single ascending doses of CARD-024 in healthy volunteers. 

  • The primary endpoint of demonstrating safety and tolerability of CARD-024 was achieved.  Additionally, significant changes in biomarkers of cardiovascular and renal disease were observed.  Notably, there was no hypercalcemia.  
Website Builder